Vijay Kumar Kuchroo

Vijay K. Kuchroo, DVM, PhD, is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women's Hospital, and Founding Director of The Gene Lay Institute of Immunology and Inflammation. An India-born immunologist, Dr. Kuchroo is a Member of the Broad Institute and investigator in the Klarman Cell Observatory. Dr. Kuchroo is renowned for discovering next-generation immune checkpoints and Th17 cells. In 2002, he cloned and characterized TIM-3 (T cell immunoglobulin and mucin-domain containing-3), the first identification of this Th1-specific inhibitory receptor that regulates macrophage activation and autoimmune disease severity (Nature, PMID 11823861). His pioneering work established TIM-3 as a major therapeutic target, with clinical trials ongoing for cancer and autoimmune diseases. He recently demonstrated TIM-3's role in regulating inflammasome activation and anti-tumor immunity (Nature 2021) and microglial function in Alzheimer's disease (Nature 2025). In 2005-2006, Dr. Kuchroo discovered Th17 cells, a pathogenic IL-17-producing T cell subset distinct from Th1/Th2 cells. His landmark 2006 Nature paper (PMID 16648838, 6,800+ citations) showing that IL-6 plus TGF-β induces Th17 differentiation while IL-6 blocks Treg development is "one of the most cited papers in immunology." This discovery revolutionized understanding of autoimmune diseases, establishing Th17 (not Th1) as drivers of multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, and psoriasis. Dr. Kuchroo is a leading authority on LAG-3, TIM-3, and TIGIT—next-generation checkpoints being harnessed clinically. His comprehensive 2016 Immunity review (PMID 27192565) elucidated their specialized functions beyond T cell exhaustion. Elected AAI Distinguished Fellow (2021), Dr. Kuchroo has received the William E. Paul Prize (ICIS, 2020), Peter Doherty Prize (2014), NIH Javits Award (2002), and National MS Society's Dystel Prize (2021). With 134,773 citations and h-index ~155, he has fundamentally shaped modern immunology and checkpoint immunotherapy.

Vijay K. Kuchroo兽医学博士、哲学博士现任哈佛医学院Samuel L. Wasserstrom神经学讲席教授、Brigham and Women's医院高级科学家、Gene Lay免疫学与炎症研究所创始主任。Kuchroo博士出生于印度,现为Broad研究所成员和Klarman细胞观测站研究员。 Kuchroo博士因发现新一代免疫检查点和Th17细胞而闻名。2002年他克隆并鉴定了TIM-3 (T细胞免疫球蛋白和黏蛋白结构域-3),这是首次发现这一Th1特异性抑制性受体调控巨噬细胞激活和自身免疫疾病严重程度 (Nature, PMID 11823861)。他的开创性工作确立TIM-3为重要治疗靶点,目前靶向TIM-3的癌症和自身免疫疾病临床试验正在进行。他近期证明TIM-3在调控炎症小体激活和抗肿瘤免疫(Nature 2021)以及小胶质细胞在阿尔茨海默病中的作用(Nature 2025)。 2005-2006年,Kuchroo博士发现了Th17细胞,一种不同于Th1/Th2的致病性IL-17产生T细胞亚群。他2006年Nature里程碑论文 (PMID 16648838, 引用6,800+次)证明IL-6与TGF-β共同诱导Th17分化而IL-6阻断Treg发育,这是"免疫学领域被引用最多的论文之一"。这一发现革新了对自身免疫疾病的理解,确立Th17(而非Th1)是多发性硬化症、炎症性肠病、类风湿性关节炎和银屑病的驱动者。 Kuchroo博士是LAG-3、TIM-3、TIGIT这些正在临床利用的下一代检查点的权威。他2016年Immunity权威综述 (PMID 27192565)阐明了它们超越T细胞耗竭的专门化功能。 Kuchroo博士2021年当选AAI杰出会士,获William E. Paul奖(ICIS, 2020)、Peter Doherty奖(2014)、NIH Javits奖(2002)和国家MS协会Dystel奖(2021)。他的研究获134,773次引用、h指数约155,从根本上塑造了现代免疫学和检查点免疫治疗。